IDEV Technologies Strengthens Commercial Leadership

WEBSTER, Texas, June 6, 2012 /PRNewswire/ -- IDEV Technologies, Inc. (IDEV), an emerging innovator in peripheral vascular devices, announced the hiring of Trent Reutiman as Vice President, Global Commercial Operations. He joins the company after successful sales and marketing positions at ROX Medical and several other start-ups. His early career was in sales and sales management at Guidant and Cordis.

In addition to Reutiman, IDEV has further supplemented the global team with additional hires in key areas including the commercial organization, product development, and operations as the company continues to develop its business through organic growth, new product launches, and geographic expansion.

"The addition of Trent to our senior management team is a reflection of our commitment to further expand our capabilities, and to execute our long term strategy," commented Christopher Owens, President and CEO of IDEV. "All the new resources bring global experience that further enhances our existing organization as we work to develop and complement our unique technology platform."

Reutiman, in this newly created role, will lead the global sales and marketing teams as the company continues to expand distribution and sales of its flagship product, the SUPERA® stent.

"I'm excited to join IDEV at this time," commented Reutiman. "With recent product launches in multiple countries in the Asia Pacific region, continued market penetration in Europe, and intense preparations for the anticipated FDA approval of the SUPERA stent in the U.S., we are setting strategies that are vital to successful commercial execution."

About IDEV Technologies, Incorporated
IDEV Technologies, Incorporated (IDEV) is an innovator and developer of next generation medical devices for use in interventional radiology, vascular surgery and cardiology. IDEV's worldwide headquarters is located in Webster, Texas and its European headquarters is located in Beuningen, The Netherlands.

The SUPERA stent is currently indicated in the United States for the palliative treatment of biliary strictures produced by malignant neoplasms and in multiple other countries for the treatment of biliary strictures produced by malignant neoplasms and for peripheral vascular use following failed percutaneous transluminal angioplasty (PTA).

For more information please visit www.idevmd.com.